Advertisement

Topics

SERI LUGANO Company Profile

23:55 EDT 22nd April 2018 | BioPortfolio


News Articles [9 Associated News Articles listed on BioPortfolio]

SERI Lugano: ParaCel Riboflavin Selected by FDA for Epi-on Cross-Linking for Keratoconus

Inventor of ParaCel Roberto Pinelli, MD released in 2011 his intellectual property rights to AVEDRO, Inc. The Switzerland Eye Research Institute has announced that the ...

NTU Singapore and SERI invent new scope to diagnose glaucoma

(Nanyang Technological University) A new 'pen camera' has been developed jointly by scientists from Nanyang Technological University, Singapore (NTU Singapore) and the Singapore Eye Research Institute...

Wavelength Pharma Names Former Sun Exec as New CEO

Iftach Seri previously served as Sun Pharmaceutical’s head of API.

Interest Mounts as GRAIN Announces ICO

LUGANO, Switzerland, Feb. 3, 2018/PRNewswire/ -- Innovative Blockchain solution for work agreements, GRAIN, which uses Ethereum smart contracts to reinvent the way we Read more...

ESMO divulga relatório de intenções sobre tratamento de suporte de paliativo

LUGANO, Suíça, 15 de dezembro de 2017 /PRNewswire/ -- A ESMO, principal organização profissional de oncologia médica, divulgou um relatório de intenções sobre tratamento de Read more...

ESMO publica un nuevo documento de posición sobre los cuidados de soporte y paliativos

LUGANO, Suiza, 15 de diciembre de 2017 /PRNewswire/ -- ESMO, la organización profesional líder en oncología médica, publicó un documento de posición sobre los cuidados Read more...

Wavelength Pharmaceuticals Names Iftach Seri as Chief Executive Officer and Tami Cohen as Chief Financial Officer

Wavelength Pharmaceuticals Ltd. (“Wavelength” or the “Company”), a former subsidiary of Perrigo Company plc that was recently acquired by SK Capital Partners, welcomes Ift...

Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy

Helsinn Healthcare SA / Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer thera...

Drugs and Medications [0 Results]

None

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Proposal of a Structured Reporting System for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging: PSMA-RADS Version 1.0.

As medical imaging has grown progressively more complicated and sub-specialized in recent decades, a number of standardized reporting systems have been proposed for a variety of imaging modalities and...

The clinical manifestation, survival outcome and predictive prognostic factors of 137 patients with primary gastrointestinal lymphoma (PGIL): Strobe compliant.

This retrospective study aimed to investigate clinical characteristics and prognostic factors in patients with primary gastrointestinal lymphoma (PGIL) of Chinese population.From January 2001 to Decem...

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma.

The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a...

Clinical Trials [10 Associated Clinical Trials listed on BioPortfolio]

SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support and Repair in Breast Reconstruction

Prospective, single center, postmarket clinical study to obtain clinical experience with the use of SERI® Surgical Scaffold for soft tissue support and repair in breast reconstruction.

Prospective, Randomized, Controlled, Clinical Study on Tolerability and Efficacy of hMG-IBSA

Purpose of the study is the evaluation of the tolerability (both local and systemic) and the clinical efficacy (in terms oocytes recovered) of subcutaneously versus intramuscularly adminis...

A Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

The study is to evaluate the efficacy of BGB-A317 assessed by Independent Review Committee (IRC) in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Ov...

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

The primary objective of the phase Ib of the study is to determine the recommended phase 2 dose (RP2D) for entospletinib (ENTO) in patients treated with R-CHOP. The primary objective of t...

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

This is an open-label, multi-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 in subjects with relapsed or refractory extranodal NK/T cell lymphoma.Efficacy...

Companies [3 Associated Companies listed on BioPortfolio]

SERI LUGANO

Helsinn Healthcare SA

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and subsidiaries in USA and Ireland. Helsinn's unique business model is focused on the licensing of phar...

Helsinn Group and DARA BioSciences, Inc.

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business mo...

More Information about "SERI LUGANO" on BioPortfolio

We have published hundreds of SERI LUGANO news stories on BioPortfolio along with dozens of SERI LUGANO Clinical Trials and PubMed Articles about SERI LUGANO for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SERI LUGANO Companies in our database. You can also find out about relevant SERI LUGANO Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record